NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Relay Therapeutics, Inc. (RLAY) Stock Analysis

Relay Therapeutics, Inc. (RLAY) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

RLAY

$19.04

+$0.03 (+0.16%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RLAY with… →

RLAY Key Statistics

As of Sep 4, 2026
Trading
Open
$18.85
Previous Close
$19.01
Day's Range
18.68–19.26
52-Week Range
3.87–21.27
Volume
2.05M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.70
Valuation
Market Cap
$4.17B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
403.14
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.56
Financials (FY)
Revenue (FY)
$15.36M+53.44%
Net Income (FY)
−$276.48M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
219.14M
1-Year Return
+376.00%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
3.06M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RLAY Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+125.06%
2025+105.34%
2024−62.58%
2023−26.31%
2022−51.35%
2021−26.11%
2020 (partial year)+18.57%

As of September 4, 2026.

RLAY Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$15.36M−$276.48M−1800.6%
2024$10.01M−$337.71M−3374.7%
2023$25.55M−$341.97M−1338.7%
2022$1.38M−$290.51M−21036.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$15.36M—−$302.74M−$276.48M−1800.6%
2024$10.01M—−$385.67M−$337.71M−3374.7%
2023$25.55M—−$379.42M−$341.97M−1338.7%
2022$1.38M—−$310.95M−$290.51M−21036.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RLAY Valuation vs Biotechnology Median

Median of 656 stocks
MetricRLAYBiotechnology medianvs median
P/S ratio403.1415.2626.4x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Relay Therapeutics, Inc. (RLAY) is capitalised at $4.17B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 202.

The 52-week range on file runs from $3.87 to $21.27. RLAY last closed at $19.04 on September 4, 2026. That is +$0.03 (+0.16%) against the previous close. The latest close sits 392.63% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $15.36M. Against the prior fiscal year total of $10.01M, that is a change of +53.44%. The same year closed with a net loss of $276.48M. The reported profit margin is 0%. Trailing earnings per share are −1.56.

Across the 4 fiscal years on file, revenue moves from $1.38M in 2022 to $15.36M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 403.14. On price-to-sales that is 26.4 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned +376.00%. Across 5 years the annualized return works out at −9.58%. The reported beta is 1.7. Annualized volatility over the trailing 6 years is 76.35%.

Growth & Income

No dividend is on file for RLAY.

2026 is still running; the price is +125.06% year to date. The strongest complete calendar year on file is 2025 at +105.34%; the weakest is 2024 at −62.58%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

Relay Therapeutics, Inc. (RLAY) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Relay Therapeutics, Inc. RLAY $4.17B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Relay Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Relay Therapeutics, Inc.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Visit website →